Industry & Policy News

[University of Tennessee Health Science Center] Hongsik Jake Cho, PhD, associate professor at the University of Tennessee Health Science Center (UTHSC), recently received a $1.56 million Rehabilitation Research and Development Award from the US Department of Veterans Affairs to research next generation treatments for post-traumatic osteoarthritis.

[University of Arkansas] The National Institutes of Health (NIH) awarded a little more than $2.5 million to researchers at the University of Arkansas to study how exercise can mitigate the decline of tissue function with aging.

[Gilead Sciences, Inc.] Gilead Sciences, Inc. announced that the US FDA has placed a partial clinical hold on the initiation of new patients in US studies evaluating magrolimab to treat AML. The FDA action follows the previously announced discontinuation of the Phase III ENHANCE study of magrolimab in higher-risk myelodysplastic syndromes.

[Nuvectis Pharma] Nuvectis Pharma, Inc. announced that NXP800 was granted Orphan Drug Designation by the US FDA for the treatment of cholangiocarcinoma.

[Artiva Biotherapeutics Inc.] AlloNK is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved natural killer cell therapy candidate designed to enhance antibody-dependent cellular cytotoxicity.

[Nature News] It is time for a redefinition of the human embryo, a team of researchers has proposed. Advances in recent years have shown that human stem cells can be used to make embryo-like structures, called embryo models, that can recreate some features of early embryo development. Such research raises ethical dilemmas because these entities don’t meet formal definitions of embryos, so are not covered by regulations governing embryo research.